Results 241 to 250 of about 699,051 (382)

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens   +14 more
wiley   +1 more source

Evaluation of enzymatic pretreatment strategies to enhance anaerobic digestion of tomato waste

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Tomato residues are a form of solid waste that can be converted into methane through anaerobic digestion (AD). However, methane production is often limited due to incomplete hydrolysis caused by the high lignocellulosic content of tomato waste.
María Eugenia Martínez   +4 more
wiley   +1 more source

Sustainable biofuel production from fish processing waste: lipase‐catalyzed hydroesterification of tilapia residual oil

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Fishing waste and byproducts, whether naturally occurring or from industrial processing, are important sources of high‐value compounds. Fertilizers, biomaterials, cosmetics, biolubricants, and biodiesel are some of the substances that can be obtained from these residues. The objective of this study was to conduct a theoretical and experimental
Patrick da Silva Sousa   +7 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy